CYBERMED NEWS - Higher Medical Scientifc Information and Research

Cancer

  • Public Health 28 - 02 - 2020

    facebook Share on Facebook

    COVID-19 : EU working on all fronts

    From day one, the European Commission’s central aim has been the protection of citizens from COVID-19, supporting Member States and the global efforts to contain its spread. Commissioner Stella Kyriakides has highlighted these ongoing efforts: “COVID-19 has shown its ability to cross borders and continents. This outbreak is a test case for existing global emergency response mechanisms as well as for our cooperation within the EU”. For the latest details on the EU’s response to COVID-19, including Q&As, speeches and Risk Assessments by ECDC, please follow the link below.

     

    World Cancer Day event

    On 4 February, World Cancer Day, the European Commission started its outreach on Europe’s Cancer Plan at an event in the European Parliament in Brussels, bringing together several testimonials and a range of stakeholders, from political leaders to health professionals and NGOs to help devise and implement an ambitious and far-reaching plan that will have a concrete impact in fighting this disease. President Von der Leyen, Vice-President Schinas and several Members of the European Parliament joined Commissioner for Health and Food Safety, Stella Kyriakides to launch the consultation.

     

    Europe’s Beating Cancer Plan: join the consultation

    The consultation on Europe's Beating Cancer Plan is now open and will last for 12 weeks until the end of April. Citizens, patients, and carers replying in their personal capacity as well as health professionals and organisations are invited to contribute their thoughts until 7 May. Stakeholders can also provide feedback to the Europe's Beating Cancer Plan roadmap.

     

    World Rare Disease Day

    On 28 February, the European Commission marked World Rare Disease Day by highlighting the call for closer collaboration to improve research, diagnosis and treatment of such diseases. Commissioner Stella Kyriakides said: “Tackling rare diseases and reducing the inequalities in treatment across the EU is a key personal priority for me. Earlier this month, I launched an EU wide public consultation on Europe’s Beating Cancer Plan, which will have a concrete impact for the 22% of cancer patients that are diagnosed with a rare form of cancer, as well as for other rare conditions.”

     

    Commission publishes its progress report on Action Plan

    On 12 February, the European Commission published its 4th progress report on the implementation of the European One Health Action Plan against Antimicrobial Resistance, which was adopted in June 2017. Since the last progress report in mid-2019, there have been number of developments. These include meetings of the AMR One Health Network and of the Health Security Committee as well as One Health visits to Member States to support the implementation of national One Health action plans.

     

    Rare Disease

    Video - Rare Disease Day 2020

    Go to related site

  • 'Independent' researchers have shares in drug companies they're testing

    facebook Share on Facebook
    'Independent' researchers have shares in drug companies they're testing image

    Independent drug trials aren't always quite so independent. Researchers are still not revealing the pay-outs they're getting from drug companies whose drugs they are testing—and in some cases they even have shares in the company.

    Around a third of researchers are not disclosing their financial conflicts of interest despite the enormous pressure from medical journals for transparency in clinical trials.

    Some researchers get speaking fees, others receive 'research grants' and others hold shares in the drug company whose drug they are reviewing, but which they are not revealing in their research that is presented as being independent.

  • 'Mind tactics' on doctors are tripling opioid prescribing

    facebook Share on Facebook
    'Mind tactics' on doctors are tripling opioid prescribing image

    Tactics from the world of behavioural science are being used on doctors to encourage them to prescribe more drugs, such as statins, opioids and the flu vaccine.

    Doctors who are exposed to techniques such as 'nudges' triple the number of prescriptions they write out, a new study has discovered.

    Nudges and other techniques from the world of behavioural science are being built into software systems that doctors access when they are treating patients. Two common 'nudges' are reminders at the point when the doctor decides on the next steps and later when their prescribing levels are compared to those of other doctors.

    The techniques are tripling the number of prescriptions being written, say researchers from the University of Pennsylvania's School of Medicine.

  • 'New opioid' painkiller scandal looms

    facebook Share on Facebook
    'New opioid' painkiller scandal looms image

    The opioid addiction scandal may be triggering the misuse of another painkiller. Prescriptions for gabapentinoids have doubled in the last few years as the opioid epidemic has been making the headlines.

    Gabapentinoids—which include gabapentin and pregabalin—are licensed as anti-seizure and nerve pain medications, but around 95 percent of prescriptions are 'off-label', meaning they are given to treat other health problems, such as migraine and fibromyalgia.

  • A little sun (and vit D supplements) help you survive cancer

    facebook Share on Facebook
    A little sun (and vit D supplements) help you survive cancer image

    Far from causing cancer, sitting out in the sun, and getting your vitamin D top-up, reduces the chances of dying from the disease.

    A little sunbathing, taking vitamin D supplements and eating foods rich in the vitamin, such as eggs and red meat, can all help you survive cancer. The vitamin also protects against heart disease and diabetes and strengthens our bones.

  • Acts of compassion help cancer patients live longer

    facebook Share on Facebook
    Acts of compassion help cancer patients live longer image

    Cancer patients live longer, or even reverse the condition, if their vagus nerve is stimulated, which can be done through meditation, yoga and compassion and gratitude, a new study has concluded.

    Survival times are four times greater in people with high vagus activity, and the cancer's progress is slowed, especially in the later stages of the disease.

    The vagus nerve, which runs from the brain stem, through the neck and thorax and ends in the abdomen, lowers our heart rate and controls food digestion. And it's involved in the three biological processes the researchers say are linked to cancer: oxidative stress or free radicals, inflammation and stress.

     

    Researchers at Vrije University in Brussels took another look at 12 studies, involving 1822 cancer patients, that had monitored heart rate variability (HRV), an indicator of vagus nerve activity. They discovered that the cancer's progress was slower in those whose vagus nerve activity was higher, and this was the case for all types of cancer.

    The effect of vagus activity was more noticeable in those whose cancers were in the late stages and treatments were less effective.

    Medical researcher Dr David Hamilton says there are four proven ways to stimulate vagus nerve activity: exercise, meditation, yoga and compassion. He says that studies by Stephen Porges at the University of Northern Carolina have shown that compassion activates the vagus nerve, and similar effects have been seen in those who practise the Buddhist 'Loving Kindness' meditation.

    (Sources: Journal of Oncology, 2018; article ID 1236787; doi.org/10.1155/2018/1236787; drdavidhamilton.com/davids-blog)

     

    https://www.wddty.com/news/2018/09/acts-of-compassion-help-cancer-patients-live-longer.html?utm_source=Boomtrain&utm_medium=email&utm_campaign=enews_04092018&bt_ee=qqaNQiCQna6BRv1h210MsK1rGdiR4kXqWbL5T7HXKeDt4Ek0xnH2OBOHY4whJPtq&bt_ts=1536055799170

     

  • Antibiotics raise risk of heart disease and cancer

    facebook Share on Facebook
    Antibiotics raise risk of heart disease and cancer image

    Although antibiotics can be life-saving drugs, they also raise the risk for a range of other serious chronic conditions, including heart disease and some cancers, new research has found.

    This is because antibiotics destroy the 'good' bacteria in the gut that protect against infections and inflammation, and inflammation is the key to many chronic diseases, from arthritis, heart problems and cancer.

    Although medicine accepts that over-use of antibiotics leads to resistance and 'super bugs', it can also be the gateway drug to most of the chronic diseases that afflict the West.

  • Breast cancer caused by bacterial imbalance, and could be treated with probiotics

    facebook Share on Facebook

    Medicine is slowly waking up to the relationship between health and the bacteria in our gut, known as the microbiome. But it's just got a whole lot more interesting still: the microbiome is all over our body, and one of the first discoveries is that breast cancer is linked to bacterial imbalances.

    Healthy breast tissue has more of a 'good' bacteria known as Methylobacterium, say researchers who have also discovered that the breast area has its own 'mini-microbiome'.

  • California says coffee causes cancer—so should you give it up?

    facebook Share on Facebook
    California says coffee causes cancer—so should you give it up? image

    A California judge has ruled that coffee shops like Starbucks must start displaying warning notices that the drinks can cause cancer—so does that mean you should give up on your favourite morning brew?

    Coffee contains acrylamide, a chemical found in many foods that are cooked to very high temperatures, and which some studies have found is a carcinogen, especially if consumed at very high quantities.

    Under proposition 65, California state law requires businesses with 10 or more employees to provide reasonable warning about the use of any chemicals that could cause cancer, birth defects or reproductive problems.

    Now superior court judge Elihu Berle has ordered Starbucks and other coffee chains to display warnings after they had failed to demonstrate that the risks were "insignificant".

  • Cancer drug helps tumours grow, study discovers

    facebook Share on Facebook
    Cancer drug helps tumours grow, study discovers image

    A major drug designed to shrink tumours in advanced breast cancer is actually helping them grow, a new study has discovered.

    Although it's been routinely used since its approval 11 years ago, researchers have only recently discovered that lapatinib (Tyverb in the UK; Tykerb in the US) could be doing more harm than good.

  • Cell phone networks cause cancer, major study concludes

    facebook Share on Facebook
    Cell phone networks cause cancer, major study concludes image

    Radio frequency radiation from cell (mobile) phone networks can cause cancer, a major $30m study has concluded. There is 'clear evidence'—which is the highest level of proof—that exposure to radiation from 2G and 3G networks in particular is carcinogenic.

    Researchers from the US's National Toxicology Program didn't test the cancer risks of newer technologies, such as 4G and 5G or wi-fi, and so can't be sure if they have similar risks.

    Although the radiation is definitely carcinogenic, people may have to be exposed to very high levels before they developed cancer, the researchers say.

  • Cell tower blamed for sudden rise in cancer cases at school

    facebook Share on Facebook
    Cell tower blamed for sudden rise in cancer cases at school image

    Parents are blaming a cell tower for a sudden rise in cancer cases among students and teachers at an elementary school and are calling to have it removed.

    Four students and three teachers at a school in Ripon, San Joaquin, California have developed cancer in the past four years—and parents are convinced that the tower, which was installed on the school grounds a few years ago, is responsible.

  • Chemical industry blocks report on cancer links

    facebook Share on Facebook
    Chemical industry blocks report on cancer links image

    A crucial report into the dangers of formaldehyde—found in building materials such as plywood and foam insulation—has been suppressed by the chemical industry. The US's Environmental Protection Agency (EPA) has delayed the release of the papers that now links the chemical to leukaemia as well as other cancers.

    Top EPA officials have refused to review the study—which means it can't be released to the public—following intensive lobbying by the industry's representative group, the American Chemistry Council (ACC).

    Although formaldehyde has been linked to several cancers in the past, the council was especially worried about the latest evidence that it could cause leukaemia, a cancer of the blood.

  • Chemo doesn't benefit the breast cancer patient (but immunotherapy just might)

    facebook Share on Facebook
    Chemo doesn't benefit the breast cancer patient (but immunotherapy just might) image

    Chemotherapy doesn't help the vast majority of women suffering from the most common form of breast cancer—but a new immunotherapy treatment just might.

    Although chemotherapy is routinely given to treat breast cancer, it doesn't help up to 70 per cent of patients, a new study has discovered. Women who undergo the traumatic and debilitating treatment were no more likely to be alive five years later than women who instead opt for hormone therapy only. And both groups had a similar risk level of the cancer recurring in those five years.

    Researchers from the Albert Einstein Cancer Center assessed the effectiveness of chemotherapy on women with the most common form of breast cancer, known as hormone receptor (HR)-positive, HER-2 negative, axillary lymph node-negative.

  • Common blood pressure drugs raise skin cancer risk seven-fold

    facebook Share on Facebook

    Some of the world's most common drugs for high blood pressure (hypertension) 'significantly' increase the risk of skin cancer, new research has discovered.

    Diuretics, or 'water pills', make skin cancer seven times more likely, especially in patients who have been taking the drugs for a long time.

     

    The drugs contain a chemical called hydrochlorothiazide, which seems to change the skin, and makes it more sensitive to the sun's UV rays, say researchers at the University of Southern Denmark.

  • CT scan quadruples brain tumour risk

    facebook Share on Facebook
    CT scan quadruples brain tumour risk image

    CT (computed tomography)—the wonder-scans that produce a 3-D image of the body—can quadruple the chances of brain cancer, a new study has discovered.

    Patients who are exposed to the highest doses of radiation from a CT scan are at the greatest risk, but even a less powerful scan still doubles the risk for a brain tumour.

    The use of CT technology has ballooned in the past 20 years because it makes diagnosis much easier as it gives a three-dimensional image of a problem area, typically the brain, or abdomen and pelvis.

    But it also releases much higher levels of radiation than a standard x-ray, and this is putting many more people, and especially children, at risk.

  • Curcumin is good for bone cancer, too

    facebook Share on Facebook
    Curcumin is good for bone cancer, too image

    Curcumin, the main ingredient in turmeric, is a natural cancer killer—and the list of cancers it can combat keeps on growing. The latest is bone cancer, and the spice could be particularly effective against osteosarcoma, the second most lethal cancer among children.

  • DR. Stefano Fais

    facebook Share on Facebook

    Dr. Stefano Fais, MD, Ph D,

    Head of Research Department of Oncology and Molecular Medicine

    Istituto Superiore di Sanità (National Institute of Health)

     

    Curriculum Vitae:

    Personal info: Data di nascita:24 Luglio 1956
    Luogo di nascita:Roma, Italia
    Nazionalità:Italiana
    Stato Civile:Sposato, 1 figlio
    Indirizzo lavorativo:Viale Regina Elena 299, 00161  Roma
    Telefono:06.49903195
    FAX:06.49903691
    e-mail:stefano.fais@iss.it

    Titoli Accademici
    •1982 LAUREA IN MEDICINA E CHIRURGIA 110/110 E LODE FACOLTA' DI MEDICINA UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA.

    • •1985 SPECIALIZZAZIONE IN GASTROENTEROLOGIA FACOLTA' DI MEDICINA UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
      •1991 DOTTORANDO IN RICERCA SCIENZE GASTROENTEROLOGICHE FACOLTA' DI MEDICINA UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
    • •1993 SPECIALIZZAZIONE IN PATOLOGIA GENERALE FACOLTA' DI MEDICINA UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
      •1994 POSTDOTTORATO IN VIROLOGIA CATTEDRA DI VIROLOGIA FACOLTA' DI MEDICINA UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
    • •1995 PROFESSORE A CONTRATTO SCUOLA DI SPECIALIZZAZIONE IN GASTROENTEROLOGIA FACOLTA’ DI MEDICINA E CHIRURGIA UNIVERSITA’ DI REGGIOCALABRIA IN CATANZARO

     Esperienze lavorative e campi di interesse

    Istituto Superiore di Sanità  I.S.S.
    (1994-2013)

     Dal 1979 ad oggi

     

     
    Laboratorio di Virologia (Ricercatore a contratto 1994-98)
    Laboratorio di Immunologia (Primo Ricercatore 1998-2002)
    Dipartimento del Farmaco (Dirigente di Ricerca 2002-2008)
    Direttore Reparto Farmaci Antitumorali (da marzo 2008)
    Posizione Attuale:
    Dirigente di Ricerca, Direttore Reparto Farmaci Anti-Tumorali.
    Dipartimento del Farmaco

    La missione del Reparto è quella principalmente di svolgere ricerca translazionale su nuovi farmaci ed approcci di terapia anti-tumorale. Fa parte integrante delle attività del reparto anche la partecipazione come esperto a commissioni per la valutazione di richieste di sperimentazioni cliniche di nuovi farmaci. Di grande rilievo è stata l’evidenza sperimentale sulla potenziale efficacia di inibitori delle pompe protoniche come nuovo presidio anti-tumorale e chemosensibilizzante. Sulla base di questi studi è stato brevettato il nuovo uso degli inibitori delle pompe protoniche (PPI) come nuovo presidio anti-tumorale e sono stati avviati due studi clinici, tutt’ora in corso, sull’uso dei PPI come chemosensibilizzanti nei pazienti con Melanoma ed Osteosarcoma.
    E’ stato inoltre finanziato uno studio clinico sull’uso dei PPI nel trattamento del carcinoma mammario che si svolgerà presso il Department of Medical Oncology, Fudan University Cancer Hospital di Shanghai, Cina. La caratterizzazione pre-clinica allo scopo di ottimizzare l’uso dei PPI nei pazienti con tumore è tutt’ora in corso.

    L’attività scientifica del reparto farmaci Anti-Tumorali è anche rivolta alla identificazione di nuovi antigeni tumorali associati ad attività   poco studiate tipiche delle cellule maligne come il cannibalismo. Esperimenti recenti hanno portato alla identificazione di un nuovo gene e del suo prodotto corrispondente ad una molecola presente solo nelle cellule ad attività metastatica.

    Inoltre, da tempo si stanno studiando le caratteristiche di microvescicole rilasciate sia da cellule normali che tumorali, chiamate exosomes. Nel reparto è stato messo a punto, e brevettato (EXOTEST), un nuovo metodo per la caratterizzazione di queste micro vescicole nei liquidi biologici. Questo metodo è stato utilizzato in uno studio clinico eseguito in 100 pazienti con melanoma maligno in stadio III-IV comparati a circa 50 donatori sani. Nel plasma dei pazienti con melanoma erano presenti livelli di exosomes 3-4 volte superiori a quelli presenti nel plasma dei soggetti normali.

    Le attività del reparto sono anche rivolte alla identificazione dei meccanismi dei resistenza ai farmaci sviluppati dai tumori. Risultati rilevanti sono stati raggiunti anche in questo campo.

    Nelle precedenti esperienze in ISS il Dr Fais ha messo a punto alcuni modelli pre-clinici per lo studio dei meccanismi di infezione da HIV-1 e per la verifica di efficacia di nuovi presidi terapeutici (laboratorio di Virologia, 1994-1998). I modelli sono costituiti da topi SCID inoculati con cellule mononucleate del sangue periferico o cellule linfoidi umane ed infettati in vivo con HIV-1. I risultati ottenuti con questi modelli sono documentati su varie pubblicazioni scientifiche.

    Nel laboratorio di Immunologia (1998-2002) il Dr Fais ha lavorato sulla messa  a punto di modelli pre-clinici per la valutazione di nuove immunoterapie anti-tumorali e sulla identificazione di meccanismi di evasione tumorale alla risposta immunitaria. I risultati di questo lavoro sono tutti documentabili su diverse pubblicazioni scientifiche.

    Il Dr Fais oltre ad essere stato presente in molte commissioni di concorso per l’assegnazione di posti di primo ricercatore, ricercatore, tecnico e borse di studio per giovani laureati, svolge le seguenti attività regolamentatorie in ISS:
    1.Esperto della Commissione Comma C allo scopo di accertare l’ammissibilità alla sperimentazione clinica di fase I in Italia di prodotto farmaceutici di nuova istituzione.
    2.Esperto AIFA per la valutazione di richieste per la sperimentazione clinica di fase II di nuovi farmaci anti-tumorali ed in ambito gastroenterologico.
    3.Membro commissione per le linee guida sulle terapie cellulari e geniche.
    4.Membro commissione per la autorizzazione all’arruolamento di pazienti in studi clinici di terapia genica e cellulare somatica (nell’ambito del comma C).
    5.Membro della commissione per l’autorizzazione in deroga alla sperimentazione animale

    Inoltre, il Dr Fais svolge regolarmente le seguenti attività:
    1. Reviewer per articoli sottomessi alla pubblicazione in numerose riviste (Oncogene, Nature Reviewes in Molecular and Cell Biology, Cancer Research, International Journal of Cancer, Cancer Letters, Lancet Oncology, Toxicology in Vitro, BMC Medical Biology, Immunobiology, European Surgical Research, Cancer Immunology Immunotherapy, Apoptosis, Biochemical Pharmacology, Experimental Oncology journal, etc)
    2..Reviewer in ambito nazionale ed internazionale per l’assegnazione di progetti ricerca in ambito oncologico.
    3.Co-relatore di tesi di laurea in varie discipline
    4.Tutor di  Ph.D students in Italia ed in Europa.
    5.External reviewer for academic positions in European countries.
    6. Negli ultimo due anni il Dr Fais è stato delegato nazionale nel Governing Council dell’Internation Agency for Research on Cancer (IARC) di Lione.

    Dal 2010 Stefano Fais è Presidente dell’International Society for Proton Dynamics in Cancer (ispdc) e nei giorni 27-28 Settembre 2010 il prima meeting europeo di ispdc è stato organizzato in ISS.

    Istituto di Virologia Università La Sapienza Roma (1992-1994) (1994-2008)
    Nei due anni passati presso l’istituto di Virologia della Sapienza, sotto la direzione e la guida del Prof. F. Dianzani e lavorando insieme alla Drssa. M. Capobianchi, il Dr. Fais ha svolto ricerche principalmente nell’ambito dei meccanismi di trasmissibilità dell’HIV. In  particolare, Il Dr Fais ha evidenziato i meccanismi attraverso cui l’HIV-1 acquisisce proteine della membrana cellulare durante il fenomeno di budding, e messo personalmente a punto una metodica in ELISA per evidenziare tali proteine su purificati virali e verificare il livello di infettività dei virioni catturati su piastre ricoperte di anticorpi diretti verso le proteine cellulari. Il Dr Fais ha inoltre dimostrato come il budding virale avvenga in maniera polarizzata dalla cellula, sfruttando le connessioni che le proteine di membrana hanno con il citoscheletro di actina. Durante i due anni passati nell’ Istituto di Virologia il Dr Fais ha acquisto competenze virologiche e di biologia molecolare, che hanno allargato sensibilmente il bagaglio di esperienze tecnico-scientifiche e stimolato nel Dr Fais un visione a 360 gradi sulle problematiche della ricerca. Durante quegli anni il Dr Fais ha anche implementato le conoscenze biotecnologiche su interferon I e II e sul ruolo dell’interferon nella patogenesi di diverse malattie.
    Durante questo periodo il Dr. Fais ha seguito un corso Post-Dottorato in  Virologia, ottendo una borsa di studio.

    Cattedra di Gastroenterologia         Clinica medica II Università La Sapienza Roma (1979-1992) (1994-2008)
    Presso la cattedra di Gastroenterologia della II Clinica Medica del Policlinico Umberto I di Roma il Dr Fais ha trascorso il periodo di formazione più lungo e forse fondamentale della sua carriera scientifica.
    Il Dr Fais sotto la supervisione del Prof. Aldo Torsoli, ma lavorando sin dall’inizio con Il Prof. Francesco Pallone, durante quegli anni ha imparato il metodo di approccio alla medicina sia dal punto di vista clinico sia dal punto di vista dell’attività di ricerca allo scopo di incrementare le conoscenze sulle malattie.
    In particolare, sin dall’inizio il Dr Fais si è occupato di malattie infiammatorie croniche intestinali (Morbo di Crohn e Colite Ulcerosa), sia dal punto di vista clinico che di ricerca delle cause patogenetiche.
    Nel 1981 il Dr Fais ha conseguito la laurea in Medicina e Chirurgia discutendo una tesi sui livelli circolanti di sottopolazioni Linfocitarie in pazienti con morbo di Crohn, usando anticorpi monoclonali messi a disposizione dal Dr Peter Beverly (University College Hospital of London) in epoca di assoluto pionierismo nell’uso di tali metodiche.
    Dal 1981 al 1992 il Dr Fais ha concentrato la sua attività di ricerca su vari aspetti della risposta immunitaria nei pazienti con morbo di Crohn. Nel 1982 il Dr Fais è stato presso Royal Infirmary di Oxforf UK, sotto la guida del Dr. Derek Jewel, imparando le metodiche per isolare cellule mononucleate ed epiteliali da frammenti di mucosa intestinale umana, trasferendo tale metodica per primo in Italia. Tra la fine del 1982 ed il 1983 il Dr Fais è stato ufficiale medico dell’Aerounatica Militare per soddisfare agli obblighi di leva.
    Nel 1984 riprendeva i suoi studi sull’infiammazione mucosale nel morbo di Crohn, arrivando ad importanti risultati pubblicati a più riprese su Gut e Gastroenterology. I risultati principali dal 1984 al 1995 circa, sono stati: (i) la dimostrazione che nei pazienti con morbo di Crohn vi sono livelli di attivazione immunitaria spontanea sia al livello periferico che intestinale; (ii) che tale attivazione porta ad una produzione costante di interferon-gamma al livello intestinale, a sua volta responsabile del continuo stato di attivazione linfocitaria , ma anche (iii) del costante reclutamento di monociti dalla periferia e della loro differenziazione in (IV) cellule giganti multinucleate, così perpetuando lo stato di infiammazione cronica. Infatti, negli ultimi periodi trascorsi presso la Cattedra di Gastroenterologia, il Dr Fais ha dedicato gran parte delle sue ricerche alla genesi delle cellule di Langhans, caratteristica tipica della infiammazione granulomatosa. I suoi dati hanno aggiunto importanti evidenze sulla genesi fusogena delle cellule giganti multinucleate in particolare a carico di monociti richiamati nel sito di infiammazione. A cavallo del periodo di passaggio dalla gastroenterologia alla virologia il Dr Fais si è anche   occupato di evidenziare le differenze fra i sincizi virali e le cellule multinucleate di Langhans.

    Agli inizi degli anni 90’ il Dr Fais ha anche studiato alcuni aspetti patogenetici del Morbo Celiaco in collaborazione con il Dr Maiuri ed il Prof. Auricchio della Cattedra di Pediatria del II Policlinico di Napoli.
    Dal 1988 al 1992 il Dr Fais ha seguito il corso di Dottorato di Ricerca in Scienze Gastroenterologiche, ottenendo il titolo di Dottore in Ricerca.

    Durante tutti gli anni passati presso la cattedra di gastroenterologia il Dr Fais non ha mai trascurato la pratica clinica dedicandosi giornalmente alla diagnosi e cura dei pazienti con malattie infiammatorie croniche intestinali, ottenendo la specializzazione in Gastroenterologia e successivamente quella in patologia generale.

    PROGETTI di RICERCA
    Il Dr Fais è attualmente responsabile scientifico dei seguenti progetti di ricerca:
    1.Coordinatore e responsabile scientifico progetto ordinario di oncologia nell’ambito del programma straordinario di oncologia del Ministero della Salute dal titolo New therapeutic strategies based on studies of tumor microenvironment and new targets identified through proteomic and genomic profile analysis”
    2.Responsabile scientifico del progetto AIFA 2005 dal titolo “Studio clinico di fase 2 sulla efficacia del pre-trattamento con inibitori delle pompe protoniche in pazienti con osteosarcoma sottoposti a poli-chemioterapia”
    3.Responsabile scientifico del progetto dal titolo “Studio pilota con cisplatino a dose fissa in combinazione con esomeprazolo (dose-ranging) come trattamento di salvataggio in pazienti con melanoma avanzato/metastatico pretrattato”, derivato da un contratto di collaborazione ISS-Astra-Zeneca.
    4.Responsabile scientifico del progetto, nell’ambito dell’associazione ISS-NHI, dal titolo “Role of environmental factors in tumor immune escape: proton pumps and acidity”
    5.UO nel WP9 (Novel therapeutic approaches) del progetto europeo FP6, dal titolo “Molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity”, acronimo CHEMORES.
    6. Responsabile scientifico del progetto Malattie Rare, nell’ambito dell’associazione ISS-NHI, dal titolo “NEW EXPERIMENTAL APPROACHES FOR INVESTIGATION ON  NEW THERAPIES AGAINST   RARE HUMAN  BONE TUMORS”.
    7.UR nel progetto FIRB dal titolo “SVILUPPO DI NUOVI FARMACI BIOLOGICI E STRATEGIE INNOVATIVE PER L'IMMUNOTERAPIA DEI TUMORI".
    8.Responsabile scientifico del progetto finanziato dal Ministero della Salute, nell’ambito della cooperazione Italia-Cina, dal titolo “STUDI PRE-CLINICI E CLINICI SULL’ INIBIZIONE DELLE POMPE PROTONICHE COME NUOVA STRATEGIA ANTI-NEOPLASTICA”.
    9. Responsabile scientifico del progetto finanziato dall’Istituto Superiore di Sanità, nell’ambito della cooperazione Italia-Cina, dal titolo “STUDIO CLINICO SULL’USO DEGLI INIBITORI DI POMPE PROTONICHE NEL TRATTAMENTO DELLE PAZIENTI CON CANCRO DELLA MAMMELLA METASTATICO”.
    10.Coordinatore della Rete Nazionale su Modelli Pre-clinici in Oncologia, nella’ambito del Programma 2 di ACC.
    11.Responsabile del Progetto Oncotec ““EFFETTO ANTI-TUMORALE SINERGICO DELLA COMBINAZIONE FRA INIBITORI DELLA TRASCRITTASI INVERSA ED INIBITORI DELLE POMPE PROTONICHE”.
    12.Co-responsabile del Progetto Oncotec “CELLULE STAMINALI TUMORALI, VESCICOLE ESOSOMIALI E MICRORNA COME NUOVO APPROCCIO PER LO SCREENING, LA DIAGNOSI E LA PROGNOSI DEI PAZIENTI CON TUMORE”.
    13.PI del Progetto AIRC” CHARACTERIZATION AND RELEVANCE OF TM9SF4, A NEW TUMOR PROTEIN ASSOCIATED TO THE METASTATIC PHENOTYPE OF HUMAN MELANOMA”

     BREVETTI
    1. “METHOD FOR TUMOR EVALUATION, IDENTIFICATION OF ANTI-TUMOR TARGETS, AND TREATMENT”, by IMED AB, box 7710, S-103 95 Stockholm, SWEDEN; Inventors: Stefano Fais, Walter Malorni, Luana Lugini and Paola Matarrese (ISS, Rome, Italy). Provisional US patent application, deposit July 14, 2003.

    1. 2. “PHARMACEUTICAL COMPOSITIONS BASED ON MUTANTS CREATED BY INSERTIONS AND DELETIONS OF EZRIN”, by Istituto Superiore di Sanità Rome Italy; Inventors: Stefano Fais and Francesco Lozupone, Istituto Superiore di Sanità, Rome Italy. UK patent application n: 0318913.1, deposit 14 August 2003.
    2. 3. ”NOVEL USE FOR PROTON PUMP INHIBITORS”, by Istituto Superiore di Sanità

    Rome Italy; Inventors: Stefano Fais and FrancescA Luciani, Istituto Superiore di

    Sanità, Rome Italy. Filed with the British Patent Office on 12 February 2004.

    1. 4. A NEW METHOD TO MEASURE AND CHARACTERIZE MICROVESICLES IN THE HUMAN BODY FLUIDS, by Hansabiomed Estonia. Inventors: Stefano fais and Mariantonia Logozzi.

    5.A NEW METASTATIC HUMAN TUMOR ASSOCIATED MOLECULE: TUMOR CANNIBALISM-ASSOCIATED PROTEIN-1 (TUCAP-1) – METHODS TO DETECT BOTH ACTIVATED GENE AND PROTEIN AND TO INTERFERE WITH GENE EXPRESSION, by Hansabiomed Estonia. Inventors: Francesco Lozupone and Stefano Fais.  

    PUBBLICAZIONI  
    Dr. Stefano FAIS: publications on peer-reviewed journals:

    Pallone F, Montano S, Fais S, Boirivant M, Signore A, Pozzilli P. Studies on peripheral blood lymphocytes in Crohn's Disease.Circulating activated T cells. Scand J Gastroenterol, 1983, 18, 1003-1008.

    Fais S, Pallone F. Patogenesi del Morbo di Crohn. RMP Gastroenterolo­gia 1983, 46, 17-18.

    Tonietti G, Ranucci A, Accinni L, Squarcia O, FAIS S, Pallone F, Pozzilli P, Di Francesco A, Menaguale L. Immunoelectronmicroscopic study of human activated T lymphocytes. IRCS Med Sci, 1984, 12, 693 .

    Tonietti G, Squarcia O, Fais S, Cascone F, Della Penna MR, Famularo G, Giacomelli R, De Matteis F. Alterations in lymphocytes subpopulations in bronchiolitis. IRCS Med Sci 1984, 12, 689-690.

    Fais S, Pallone F, Squarcia O, Boirivant M, Pozzilli P. T cell early activation antigens expressed by peripheral lymphocytes in Crohn's Disease. J Clin Lab Immunol, 1985, 16, 75-76

    Pallone F, Squarcia O, Fais S, Boirivant M, Biancone L, Tonietti G. T cell differentiation antigens expressed by peripheral blood lymphocy­tes in Crohn's Disease. Boll Ist sieroter milan, 1985, 64, 394-399.

    Tonietti G, Accinni L, Ranucci A, Squarcia O, Fais S, Pallone F, Di Francesco A, Menaguale L, Pozzilli P. Immunoelectronmicroscopic studies of activated reactive and neoplastic T lymphocytes. In the cytobiology of leukemias and lymphomas. D Quaglino and FGJ Hayhoe Eds.Serono Symposia n 20. Raven Press, New York, 1985, 321-326.

    Paganelli R, Pallone F, Montano S, Le Moli S, Matricardi PM, Fais S, Paoluzi P, D'Amelio R, Aiuti F. isotypic analysis of antibody response to a food antigen in inflammatory bowel disease. Int Archs Allergy appl Immun, 1985, 78, 81-85

    Boirivant M, Fais S, Squarcia O, Pallone F. Suppressor T cell function in inflammatory bowel disease. Problems and pitfalls. Ital J Gastroenterol, 1985, 17, 285-286

    Boirivant M, Pallone F, Prantera C, Simi M, Fais S, Zannoni F,  Torsoli A. Conservative management of small intestinal obstruction in Crohn's Disease. Ital J Gastroenterol, 1986, 18, 12-14.

    Pallone F, Matricardi PM, Squarcia O, Fais S, Le Moli S, Boirivant M, Paoluzi P, D'Amelio R. Raised serum levels of IgM-Rheumatoid factor and anti-F(ab')2 autoantibodies in patients with active inflammatory bowel disease. J Clin Lab Immunol, 1986, 19, 175-180.

    Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocy­tes in Crohn's Disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activa­tion antigens. GUT, 1987, 28, 745-75.

    Fais S, Pallone F, Squarcia O, Biancone L,  Ricci F, Paoluzi P, Boirivant M. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol, 1987, 68, 605-612

    Fais S, Pallone F, Nava C, Magnani M. Lymphocyte activation by B subtilis sporae. Boll Ist Sieroter Milan, 1987, 66, 425-429.

    Fais S, Pallone F, Scano G, Paganelli R, Aiuti F. Crohn's Disease and HIV infection. Evidence against an association. Ital J Gastroenterol, 1987, 19, 264-266.

    Biancone L, Paganelli R, Fais S, Squarcia O, D'Offizi GP, Pallone F. Peripheral and intestinal lymphocyte activation after in vitro exposure to cow's milk antigens in normal subjects and in patients with Crohn's Disease. Clin Immunol Immunopathol, 1987, 45, 491-498.

    Pallone F, Fais S, Capobianchi MR. HLA-D region antigens on isolated human colonic epithelial cells. Enhanced expression in inflamma­tory bowel disease and in vitro induction by different stimuli. Clin Exp Immunol, 1988, 74, 75-79.

    Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of Serum C Reactive Protein levels in Crohn's Disease. Results of a prospective longitudinal study. J Clin Gastroente­rol, 1988, 9, 401-405.

    Fais S, Pallone F. Ability of human colonic epithelium to express the 4F2 antigen, CALLA and the transferrin receptor in response to different stimuli. Gastroenterology 1989; 97: 1435-41.

    Torsoli A, Barbara L, Paoluzi P, Pallone F, Habib FI, Delle Fave GF, Vernia P, Fais S, Severi C, Capurso L, Prantera C. Roma88: Some data from a Post-Congress Survey. Gastroenterology International, 1989, 1, 55-61.

    Annibale B, Fais S, Boirivant M, Delle Fave GF, Pallone F. Effect of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans. Gastroenterology 1990; 98(6):1693-8.

    Boirivant M, Quintieri F, Pugliese O, Famularo G, Fais S, Pallone F. A limiting dilution analysis of activated circulating B cells in Crohn's disease. J Clin Immunol 1990; 10: 128-34.

    Torsoli A, Fais S, Ulissi A, Sebastiani R, Dowling RH. The export of European Gastrintestinal Science: the case for an annual scientific meeting in Europe. Gastr Internat 1990;4: 173-6.

    Pallone F, Fais S, Annibale B, Boirivant M, Morace S, Delle Fave G. Modulatory effects of somatostatin and Vasoactive Intestinal Peptide on human intestinal lymphocytes. Ann N Y Acad Sci 1990;594:408-10.

    Sirianni MC, Tagliaferri F, Fais S, Annibale B, Pallone F, Delle Fave G. Effect of VIP Neuropeptide on natural killer activity from peripheral blood lymphocytes of normal subjects. Ann N Y Acad Sci 1990;594:420-22. 

    Fais S, Delle Fratte F, Mancini F, Cioni V, Guadagno M, Vetrano G, Pallone F. HLA-DR expressing epithelial cells in the human cervical epithelium. Relation to viral infection and to activated mononuclear cells infiltrate. J Clin Pathol 1991;44: 290-292.

    Sirianni MC, Fais S, Annibale B, De Luca S, Boirivant M, Delle Fave G, Pallone F.Gut neuropeptides and the immune system. Adv Neuroimmu­nol 1991; 1: 173-179 .

    Fais S, Delle Fratte F, Mancini F, Cioni V, Guadagno M, Pallone F, Vetrano G.Presenza di antigeni del complesso maggiore di istocompatibi­lità di classe II sull'epitelio cervicale in corso di infezione da HPV. Relazione con la presenza "in loco" di linfociti attivati. Giorn It Ost Gin 1991; 6: 361-364.

    Boirivant M, Pallone F, Ciaco A, Leoni M, Fais S, Torsoli A. Usefu­lness of fecal alpha1-antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis Sci 1991; 36:347-352. 

    Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle Fave GF. Effects of somatostatin on human intestinal lamina propria lympho­cytes. Modulation of lymphocyte activation. J Neuroimmunol 1991, 31: 211-219.

    Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dian­zani F, Torsoli A. Spontaneous release of interferon-gamma by intesti­nal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon-gamma inducers. GUT 1991, 32; 403-407.

    Squarcia O, Fais S, Boirivant M, Di Paolo MC, Marcheggiano A, Iannoni C, Paoluzi P, Pallone F. Phenotypes and spontaneous immunoglo­bulin production in mononuclear cells suspensions isolated from colonic biopsies of patients with mild active and quiescent ulcerative colitis. Gastr Clin Biol 1991 ; 15: 194-198. 

    Biancone L, Boirivant M, Fais S, Ricci GL, Paganelli R, Pallone F.Serum immunomodulatory factors in gastrointestinal diseases. A 30.000-50.000 serum fraction capable of modulating lymphocyte activa­tion. Clin Exp Immunol 1991; 83: 401-406.

    Fais S. Lymphocyte traffic and adhesion molecules in the gut. It J Gastroenterol 1991; 23: 395.

    Fais S, Maiuri L, Pallone F, De Vincenzi M, De Ritis G, Troncone R, Auricchio S.Gliadin-induced changes in the expression of MHC-class II antigen by human small intestinal epithelium. Organ culture studies with coeliac disease mucosa. Gut , 1992, 33: 472-475. 

    Sirianni MC, Annibale B, Tagliaferri F, Fais S, De Luca S, Pallone F, Delle Fave G, Aiuti F. Modulation of human natural killer  activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Reg Pept 1992; 38: 79-87.

    Capobianchi MR, Fais S, Mercuri F, Boirivant M, Dianzani F, Pallone F. Interferon-alpha(IFN-a) production by intestinal mononuclear cells.Response to virus in control subjects and in Crohn's disease. Gut 1992; 33: 897-901.

    Prantera C, Pallone F, Cottone M, Brunetti G, Miglioli M and THE ITALIAN IBD STUDY GROUP. Oral 5-Aminosalycilic Acid (Asacol) in the maintenance treatment of Crohn's disease . Gastroenterology 1992; 103; 363-368.

    Capobianchi MR, Fais S, Di Paolo MC, Agostini D, Paoluzi P, Pallone F, Dianzani F. Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology. Clin Exp Immunol 1992; 90: 95-97.

    Pallone F, Fais S, Boirivant M, Marcheggiano A, Iannoni C, Biancone L, Agostini D. Malattie gastroenteriche e immunità. Aggiornamento Medico, 16; 1992.

    Pallone F, Fais S, Capobianchi MR. Evidence against an autoimmune aetiology for inflammatory bowel disease. Gut 1992; 33: 1008.

    Pallone F, Boirivant M, Fais S, Luzza F, Doldo P, Monteleone G, Aloi A. Antibacterial drugs in Crohn's disease. It J Gastroenterol 1992; 24 Suppl 2: 17-18.

    Fais S, Capobianchi MR, Marcheggiano A, Iannoni C, Pallone F. MHC-Class II antigens on the epithelial cells of the human gastroin­testinal tract. Gastroenterology 1992 ;102:377-378.

    Capobianchi MR, Ameglio F, Cordiali Fei P, Castilletti C, Mercuri F, Fais S, Dianzani F. Coordinate induction of IFN-alpha and -gamma by recombinant HIV-1 glycoprotein 120. AIDS Res Huma Retrovir 1993; 957-61.

    De Maria R, Fais S, Silvestri M, Frati L, Pallone F, Santoni A, Testi R. Continuous in vivo activation and transient hyporesponsiveness to TCR/CD3 triggering of human gut lamina propria lymphocytes. Eur J Immunol 1993; 23: 3104-8.

    Boirivant M, Fais S, Annibale B, Agostini D, Delle Fave GF, Pallone F. Vasoactive intestinal polypeptide (VIP) modulates the "in vitro" IgA production by human intestinal lamina propria lymphocytes. Gastroentero­logy, 1994; 106: 576-82.

    Ameglio F, Capobianchi MR, Castilletti C, Cordiali Fei P, Fais S,  Trento E, Dianzani F. Recombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells. Correlation with the induction of other cytokines. Clin Exp Immunol, 1994; 95: 455-58.

    Capobianchi MR, Fais S, Ameglio F, Castilletti C, Gentile M, Dianzani F. A simple and reliable method to detect cell membrane antigen on the envelope of HIV-1. J Infect Dis 1994, 169: 886-889.

    Fais S, Burgio VL, Silvestri M, Capobianchi MR, Pacchiarotti A, Pallone F. Multinucleated Giant Cells (MGC) generation induced by interferon gamma. Changes in the expression and distribution of the intercellular adhesion molecule-1 (ICAM-1) during macrophages fusion and MGC formation. Lab Invest  1994, 71: 737-44.

    Sirianni MC, Annibale B, Fais S, Delle Fave G. Inhibitory effect of Somatostatin-14 and some analogues on human natural killer cell activity. Peptides 1994, 15: 1033-36.

    Fais S, Capobianchi MR, Silvestri M, Mercuri F, Pallone F, Dianzani F. Interferon expression in Crohn's disease patients: increased interfe­ron-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994,14: 235-8.

    Fais S. Is insulitis a Th1- or Th2 mediated disease? Implications for preventive therapy in type I diabetes. Diabetes Prevention and Therapy 1994; 8: 4-5.

    Menè P, Fais S, Cinotti GA, Pugliese F, Luttmann W, Thierauch KH. Regulation of U937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents. Nephrol Dial Transplant 1995, 10: 481-9.

    Fais S, Capobianchi MR, Abbate I, Castilletti C, Gentile M, Cordiali Fei P, Ameglio F, Dianzani F. Uniderectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of in­tercellular adhesion molecule-1 and HIV-1 viral matrix protein. AIDS 1995, 9: 329-35.

    Scheglovitova O, Scanio V, Fais S, Papadia S, Abbate I, Castilletti C, Dianzani F, Capobianchi MR. Antibody to ICAM-1 mediates enhancement of HIV-1 infection of human endothelial cells. Arch Virol 1995, 140: 951-958.

    Castilletti C, Capobianchi MR, Fais S, Abbate I, Ficociello B, Ameglio F, Cordiali Fei P, Santini SM, Dianzani F. HIV type 1 grown on IFN gamma-treated U937 cells shows selective increase in virion-associated ICAM-1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Huma Retrovirus 1995, 11: 547-553.

    Burgio VL, Fais S, Boirivant M, Perrone A, Pallone F. Increased peripheral monocytes and naive T cells recruitment and activation in Crohn's disease. Gastroenterology 1995, 109: 1029-38 (di questo lavoro è stata pubblicata sulla copertina dello stesso numero di Gastroenterology una foto a colori).

    DeMaria R, Fais S and Testi R. Persistent in vivo activation and transient anergy to TCR/CD3 stimulation of normal human intestinal lymphocytes. Adv Exp Biol   1995, 317A:43-46.

    Maiuri L, Troncone R, Fais S, Coletta S, Picarelli A, Pallone F. Crypt epithelial cells express the 4F2 antigen in untreated coeliac mucosa.. . Adv Exp Biol   1995, 317B: 1363-5.

    Abbate I, Capobianchi MR, Fais S, Castilletti C, Mercuri F, Cordiali Fei P, Ameglio F, Dianzani F. Host cell antigenic profile acquired by HIV-1 progeny is a marker of its cellular origin. Arch Virol 1995, 140: 1849-54.

    Santini SM, Rizza P, Logozzi MA, Sestili P, Gherardi G, Lande R, Lapenta C, Belardelli F, Fais S. The SCID mouse reaction to human PBL engraftment: neutrophil recruitment, induced expression of a wide spectrum of murine cytokines and mouse leukopoiesis including thymic differentiation. Transplantation 1995, 60: 1306-14.

    Fais S and Pallone F. Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines. Gut 1995, 37: 798-801.

    Rizza P, Santini SM, Logozzi MA, Lapenta C, Sestili P, Gherardi G, Lande R, Spada M, Parlato S, Belardelli F, Fais S. T cell dysfunctions in hu-PBL-SCID mice infected with HIV-1 shortly after reconstitution. The in vivo effects of HIV on highly activated immune cells. J Virol 1996,70: 7958-64.

    Fais S, Borghi P, Gherardi G, Logozzi MA, Belardelli F, Gessani S. HIV-1 induces cellular polarization, intercellular adhesion molecule-1 redistribution and multinucleated giant cell generation in human primary monocytes but not in monocyte-derived macrophages. Lab. Inv. 1996, 75: 783-90.

    Fais S, Burgio L, Capobianchi MR, Gessani S, Pallone F, Belardelli F. The biological relevance of polykarions in the immune response. Immunology Today 1997, 18: 522-526.

    Lapenta C, Fais S, Rizza P, Spada M, Logozzi MA, Parlato S, Santini SM, Pirillo M, Belardelli F, Proietti E. U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Res 1997,36: 81-90.

    Santini SM, Spada M, Parlato S, Logozzi MA, Lapenta C, Proietti E, Belardelli F and Fais S. Treatment of severe combined immunodeficiency (SCID) mice with anti-murine granulocyte monoclonal antibody improves human leukocyte xenotrasplantation. Trasplantation 1998, 65: 416-420.

    Lapenta, C., S. Parlato, M. Spada, S.M. Santini, P. Rizza, M. Logozzi, E. Proietti, Belardelli F., and Fais S. Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through In vivo upregulation of CCR5: In vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS. J. Virol. 1998 72:10323-10327.

    Lapenta, C, M. Boirivant, M. Marini, S.M. Santini, M. Logozzi, M. Viora, F. Belardelli, Fais S. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur. J. Immunol. 1999, 29: 1202-1208.

    Rozera C, Mecchia M, Gresser I, Bandu MT, Proietti E, Venditti M, Santini SM, FAIS S, Belardelli F and Ferrantini M. IFNa1 gene transduced Esb tumor cells are rejected by host-mediated mechanisms in spite of the resistance of the parental tumor to the therapy with IFNa1. Cancer Gene Therapy 1999, 6: 246-253.

    Monini P, Colombini S, Sturzl M, Goletti D, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Aschler G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, Yarchoan R, Gallo RC, Ensoli B. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi’s sarcoma. Blood 1999, 93: 4044-4058.

    Fais S, Lapenta C, Santini SM, Spada M, Parlato S, Logozzi M, Rizza P, Belardelli F. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection.  J. Virol. 1999, 73:6453-9.

    Puddu P, Fais S, Luciani F, Gherardi G, Dupuis ML, Romagnoli G, Ramoni C, Cianfriglia M, Gessani S. Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest. 1999 79:1299-309.

    Lapenta C, Santini SM, Proietti E, Rizza P, Logozzi M, Spada M, Parlato S, Fais S, Pitha PM, Belardelli F. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells. Virology 1999 263:78-88.

    Parlato, S., S. M. Santini, C. Lapenta, M. Spada, M. Logozzi, P. Rizza, E. Proietti, F. Belardelli, and Fais S. Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of latently infected cells through a massive Fas-mediated autocrine suicide of uninfected cells. Importance of CD4+ T cell differentiation in the pathogenesis of HIV-1 infection. Cell Death Differ 2000, 7: 37.

    Fais S, Luciani F, Logozzi M, Parlato S, Lozupone F Linkage between cell membrane proteins and actin-based cytoskeleton: the cytoskeletal-driven cellular functions. Histol Histopathol 2000 Apr;15(2):539-49.

    Lozupone F, Luciani F, Venditti M, Rivoltini L, Pupa S, Parmiani G, Belardelli F and Fais S. Murine granulocytes control human tumor growth in SCID mice. Int J Cancer. 2000 87:569-73.

    Parlato S, Giammarioli AM, Logozzi M, Lozupone F, Matarrese P, Luciani F, Falchi M, Malorni W and Fais S. CD95 (apo-1/fas) linkage to the actin cytoskeleton through ezrin in human t lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway . EMBO J. 2000 19: 5123-5134.

    Rizza, P., Fais S., Pini C., Proietti, F., Belardelli, F. First International Workshop on Human/SCID Mouse Models. J Biol Regul Hom Ag. 2001 2: 170-4.

    Fiorentini C, Falzano L, Fabbri A, Stringaro A, Logozzi M, Travaglione S, Contamin S, Arancia G, Malorni W, Fais S. Activation of rho gtpases by cytotoxic necrotizing factor 1 induces macropinocytosis and scavenging activity in epithelial cells. Mol Biol Cell. 2001 Jul;12(7):2061-73.

    Giammarioli, A.M., Garofalo, T., Sorice, M., Misasi, R., Gambardella, L., Gradini, R., Fais S., Pavan, A., Malorni, W., (2001) GD3 glycosphingolipid contributes to Fas-mediated apoptosis via association with ezrin cytoskeletal protein. FEBS. Lett. 506, 45-50.

    Parlato S,   Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M,  Giammarioli A ,  Malorni W , Fais S, Belardelli F. Expression of CCR-7, MIP-3b and Th-1 Chemokines in Type I IFN-induced Monocyte-derived Dendritic Cells: Importance for the Rapid Acquisition of Potent Migratory and Functional Activities. Blood. 2001 15;98(10):3022-9.

    Luciani F,  Molinari A, Lozupone F,  Calcabrini A, Lugini L,  Stringaro A, Puddu P,  Arancia G, Cianfriglia M,  Fais S. P-glycoprotein/actin association through erm family proteins: a role in p-glycoprotein function in human cells of lymphoid origin. Blood. 2002 Jan 15;99(2):641-8.

    Fais S., 2002. Importance of the state of activation and/or differentiation of CD4+ T cells in AIDS pathogenesis. Trends Immunol., 23:128-129.

    Andreola, G., Rivoltini, L., Castelli, C., Huber V., Perego, P., Deho, P., Squarcina, P., Lozupone, F., Lugini, L., Stringaro, A., Arancia, G., Parmiani, G.,  Fais S., (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FASL- bearing microvesicles. J Exp Med, 195, 1303-1316.

    Travaglione S, Falzano L, Fabbri A, Stringaro A, Fais S, Fiorentini C. Epithelial cells and expression of the phagocytic marker CD68: scavenging of apoptotic bodies following Rho activation. Toxicol In Vitro 2002 Aug;16(4):405-11.

    Fabbri A, Falzano L, Travaglione S, Stringaro A, Malorni W, Fais S, Fiorentini C. Rho-activating Escherichia coli cytotoxic necrotizing factor 1: macropinocytosis of apoptotic bodies in human epithelial cells. Int J Med Microbiol 2002 Feb;291(6-7):551-4.

    Ramoni, C., Luciani, F., Spadaio, F., Lugini, L., Lozupone, F., Fais S.,  (2002) Differential expression and distribution of ezrin, radixin and moesin in human natural killer cells. Eur J Immunol 32, 3059-65.

    Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002, 188: 97-113.

    Lozupone, F., Rivoltini, L., Luciani, F., Venditti, M., Lugini, L., Cova, A., Squarcina, P., Parmiani, G., Belardelli, F. and Fais S. Adoptive transfer of an anti-MART-127-35-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J. Immunol., 33:  556-566, 2003.

    Fais S and Malorni W. Leukocyte uropod formation and membrane/cytoskeleton linkage in immune interactions. J Leukoc Biol. 2003 73: 556-63.

    Lugini L, Lozupone F,  Matarrese P, Funaro C, Luciani F, Malorni W, Rivoltini L, Castelli C, Parmiani G and Fais S .Potent phagocytic activity discriminate metastatic and primary human malignant melanoma: a key role of ezrin. Lab Invest. 2003  83: 1555-67.

    Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, Luciani F, Lugini L, Federici F, Ramoni C, Rivoltini L, Parmiani G, Belardelli F, Rivera  P , Marcenaro S, Moretta L and Fais S. Effect of human NK and gamma/delta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 2004  64: 378-385.

    Lozupone F, Lugini L, Matarrese P, Luciani F, Federici C, Iessi E, Margotti P, Stassi G, Malorni W and Fais S. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem. 2004, 10: 9199-9207. 

    Luciani F, Matarrese P, Giammarioli AM, Lugini L,  Lozupone F,  Federici C,  Iessi E , Malorni W  and Fais S. CD95/phosphorylated ezrin association underlies HIV-1 gp120/IL-2 induced  susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting T lymphocytes. Cell Death Differ. 2004 11(5):574-82.

    Fais S. A role for ezrin in a neglected metastatic tumor function.
    Trends Mol Med. 2004 Jun;10(6):249-50.

    FAIS S.  Se i tumori fossero cannibali. Sapere Giugno 2004, pp.68-75.

    Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. J Natl Cancer Inst. 2004 Nov 17;96(22):1702-1713.

    Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?  Expert Opin Biol Ther. 2005 Apr;5(4):463-76.

    Huber V,   Fais S,   Iero M,   Lugini L,  Canese P,  Squarcina P,  Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L . Human Colorectal Cancer Cells Induce T Cell Death through Release of Pro-Apoptotic Microvesicles: Role in Immune Escape. Gastroenterology 2005 Jun;128(7):1796-804.

    De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance.       Expert Opin Pharmacother. 2005 Jul;6(7):1049-54.

    Fais S, De Milito A., and Lozupone F. The role of Fas to ezrin association in Fas-mediated apoptosis. Apoptosis. 2005 Oct;10(5):941-7.

    De Milito A and FAIS S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncology   2005,  1 (6): 779-786

    Lugini L,   Matarrese P, Tinari A,  Lozupone F,  Federici C,   Iessi E,   Gentile M,   Luciani F,   Permiani  G,   Rivoltini L,  Malorni W,  Fais S . Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006 66: 3629-3638.

    Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRAS(Q61R) and BRAF(V600E) mutations at the single-cell level in the same human melanoma.   Oncogene. 2006 Jun 8;25(24):3357-64.

    Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L. Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-{beta}-Mediated Suppressive Activity on T Lymphocytes. Cancer Res. 2006 Sep 15;66(18):9290-8.

    Fluur C, De Milito A, Fry TJ, Vivar N, Eidsmo L, Atlas A, Federici C, Matarrese P, Logozzi M, Rajnavolgyi E, Mackall CL, Fais S, Chiodi F, Rethi B. Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection.    J Immunol. 2007 Apr 15;178(8):5340-50.

    De Milito A, Iessi E, Logozzi MA, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S. Proton pump inhibitors induce apoptosis of human B cell tumors through a caspase-independent mechanism involving reactive oxigen species. Cancer Res. 2007 Jun 1;67(11):5408-17. S.

    Fais S, Cannibalism: A way to feed of metastatic tumors, Cancer Lett. 2007 Dec 18;258(2):155-64.

    Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity.    Cell Death Differ. 2008 Jan;15(1):80-8.

    Fais S,   De Milito A,   You H, and  Qin W. Targeting Vacuolar H+-ATPases as a New Strategy against Cancer. Cancer Res. 2007 Nov 15;67(22):10627-30.

    Federici C, Brambilla D, Lozupone F, Matarrese P, De Milito A, Lugini L, Iessi E,  Cecchetti S, Marino ML, Perdicchio M, Logozzi M, Spada M, Malorni W, Fais S. Pleiotropic function of ezrin in human metastatic melanoma. Int J Cancer accepted for publication.

    Huber V, Filipazzi P, Iero M, Fais S, Rivoltini L.  More insights into the immunosuppressive potential of tumor exosomes.J Transl Med. 2008 Oct 30;6:63.

    You H, Jin J, Shu H, Yu B, De Milito A, Lozupone F, Deng Y, Tang N, Yao G, Fais S, Gu J, Qin W. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells.  Cancer Lett. 2009 Jul 18;280(1):110-9.

    Federici C, Brambilla D, Lozupone F, Matarrese P, de Milito A, Lugini L, Iessi E, Cecchetti S, Marino M, Perdicchio M, Logozzi M, Spada M, Malorni W, Fais S. Pleiotropic function of ezrin in human metastatic melanomas. Int J Cancer. 2009 Jun 15;124(12):2804-12.

    Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L, Fais S. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4(4):e5219.

    Brambilla D, Fais S. The Janus-faced role of ezrin in "linking" cells to either normal or metastatic phenotype. Int J Cancer. 2009 Nov 15;125(10):2239-45.

    Muratori C, Cavallin LE, Krätzel K, Tinari A, De Milito A, Fais S, D'Aloja P, Federico M, Vullo V, Fomina A, Mesri EA, Superti F, Baur AS. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe. 2009 Sep 17;6(3):218-30.

    De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010 Jul 1;127(1):207-19

    Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, Colone M, Tatti M, Sargiacomo M, Fais S. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009 Dec 4;284(49):34211-22.

    Lozupone F, Perdicchio M, Brambilla D, Borghi M, Meschini S, Barca S, Marino ML, Logozzi M, Federici C, Iessi E, de Milito A, Fais S. The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells. EMBO Rep 2009 12:1348-1354.

    Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010 May;267(5):515-25.

    Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010 May 8;29:44.

    Fais S. Moulding the shape of a metastatic cell. Leuk Res. 2010 Jul;34(7):843-7.

    Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C, Chiesi A, Pouysségur J, Gatenby RA, Rivoltini L, Fais S. Proton dynamics in cancer. J Transl Med. 2010 Jun 15;8:57.

    M L Marino, S Fais, M Djavaheri-Mergny, A Villa, S Meschini, F Lozupone, G Venturi, P Della Mina, S Pattingre, L Rivoltini, et al.  Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells.Cell Death & Disease 1, e87 (21 October 2010).

    Brambilla D, Zamboni S , Federici C , Lugini L ,  Lozupone F, De Milito A , Cecchetti S, Cianfriglia M , Fais S. P-glycoprotein binds to ezrin at amino acid residues 149 through 242  in the ferm domain and plays a key role in the multi-drug resistance of human osteosarcoma. In J Cancer 2011 Jul 21.

    Fais S, Fauvarque MO. TM9 and cannibalism: how to learn more about cancer by studying amoebae and invertebrates. Trends Mol Med. 2011 Oct 14.

  • Drinking every day raises cancer risk

    facebook Share on Facebook
    Drinking every day raises cancer risk image

    Drinking a little alcohol every day—even a single glass or two—increases your risk of cancer, but only just a little bit.

    Drinking one drink every day for 10 years, or two drinks a day for five years, raises the risk by 5 percent.

  • Dummy placebo pills help cancer patients overcome fatigue

    facebook Share on Facebook

    Such is the healing power of the mind that placebo pills—'dummy' tablets that have no active chemical ingredients—are helping cancer survivors overcome fatigue, one of the worst conditions they have to endure after treatment has finished.

    And perhaps the most astonishing thing is that the patients were told that they were taking a placebo—and it was still working. In fact, many of the patients pleaded with the researchers to be given more of the dummy tablets, but, for ethical reasons, their request was refused.

    The 74 cancer survivors who took part in the placebo study were all suffering from moderate to severe fatigue, and they were either given an 'open label' placebo—which means they were told beforehand—or they continued their current treatment for their tiredness.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.